CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence. Early (≤3 days) intratumoral presentation of CAR T cells post-treatment is a su...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Jin, Linchun, Tao, Haipeng, Karachi, Aida, Long, Yu, Hou, Alicia Y., Na, Meng, Dyson, Kyle A., Grippin, Adam J., Deleyrolle, Loic P., Zhang, Wang, Rajon, Didier A., Wang, Qiong J., Yang, James C., Kresak, Jesse L., Sayour, Elias J., Rahman, Maryam, Bova, Frank J., Lin, Zhiguo, Mitchell, Duane A., Huang, Jianping
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6728370/
https://ncbi.nlm.nih.gov/pubmed/31488817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-11869-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados